Semaglutide Shortage Is Over, Closing the Window for Compounded Copies

What Happened

The semaglutide shortage that reshaped the GLP-1 market is officially over. Industry reports confirm that branded supply has recovered to the point where the drug no longer qualifies for shortage-driven compounding flexibility, closing the legal window that allowed compounding pharmacies and telehealth platforms to mass-produce copies of Novo Nordisk's blockbuster injectable.

With supply restored, regulators have little patience left for operators still selling compounded semaglutide. Enforcement attention is shifting from supply management to accountability — bad news for the gray market that grew up during the shortage.

Who Is Affected

• Compounding pharmacies and outsourcing facilities that built high-volume semaglutide operations during the shortage now face a shrinking legal basis for that business.
• Telehealth platforms built on compounded supply must transition patients to branded product or risk enforcement.
• Patients moving off compounded copies may encounter higher costs and insurance friction along the way.
• Researchers sourcing material outside the pharmacy system face a market in flux, with more sellers exiting and the remainder making unverified claims.

Timeline

• 2022-2023 — Demand for semaglutide outpaces supply; the drug lands on the FDA shortage list and compounding expands rapidly.
• 2024-2025 — Novo Nordisk invests heavily in manufacturing capacity; supply steadily improves while compounding volumes peak.
• 2026 — The shortage is resolved and grace periods expire. Federal channels have logged more than 1,700 problem reports tied to compounded semaglutide and tirzepatide — see our earlier coverage — and border screening of GLP-1 ingredients has tightened.
• September 2026 — Industry reports confirm the shortage era is definitively closed.

What This Means for Researchers

The end of the shortage removes the ambiguity that gray-market sellers exploited for years. While branded supply was scarce, "we're filling a gap" was a workable defense; with supply restored, selling compounded or research-grade semaglutide for human use is simply unlawful. For legitimate research buyers, the practical effect is a market that is smaller but riskier at the margins — remaining sellers face financial pressure and thinner oversight, so independent verification matters more than ever. A certificate of analysis supplied by the seller is not enough; batch-level third-party testing is the new baseline for anyone who takes their work seriously.

How to Verify Your Peptides

• Our guide to how peptide testing works covers purity, identity, and why seller-supplied certificates fall short.
• Compound references include semaglutide testing and tirzepatide testing.
• For independent analysis, see our third-party testing lab directory and our testing FAQ.

Safe Alternatives

• Review our research profiles of semaglutide and tirzepatide before sourcing any GLP-1 material.
• For other research-stage compounds such as retatrutide, insist on batch-specific analytical documentation.
• Source only from suppliers in our vendor directory that publish current third-party test results.

Sources

• Industry reports
• Regulatory announcements